Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in oral hypoglycemic agents.

Shinkai1

  • 1Central Pharmaceutical Research Institute, JT Inc., 1-1 Muracaki-cho, Takatsuki, Osaka, 569-1125, Japan.

Drug Discovery Today
|June 4, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A self-assembled porphyrin-based dimeric capsule constructed by a Pd(II)-pyridine interaction which shows efficient guest inclusion

Organic letters·2000
Same author

Asymmetry in the nonmesonic weak decay of polarized (5)(Lambda)He hypernuclei

Physical review letters·2000
Same author

Sol-Gel Polycondensation of Tetraethoxysilane in a Cholesterol-Based Organogel System Results in Chiral Spiral Silica.

Angewandte Chemie (International ed. in English)·2000
Same author

Genetic association analysis between CYP2D6*2 allele and tardive dyskinesia in schizophrenic patients

Psychiatry research·1999
Same author

Rapid Coagulation of Langmuir-Blodgett Mesoscopic Bands on Mica by Monovalent Ions.

Journal of colloid and interface science·1999
Same author

Erratum: Dynamics of topological defects and inflation

Physical review. D, Particles and fields·1996

New treatments for type 2 diabetes focus on improving insulin sensitivity and secretion. These agents offer better glycemic control to reduce chronic complications in diabetic patients.

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Type 2 diabetes management is challenging due to difficulties in maintaining optimal blood glucose levels.
  • Hyperglycemia in type 2 diabetes results from insulin resistance and impaired insulin secretion.
  • Chronic complications of diabetes underscore the need for improved glycemic control.

Purpose of the Study:

  • To review two novel classes of hypoglycemic agents for type 2 diabetes.
  • To highlight agents that address both insulin resistance and defective insulin secretion.

Main Methods:

  • Review of recent literature on new hypoglycemic agents.
  • Focus on insulin sensitizers and short-acting insulinotropic agents.

Main Results:

  • The introduction of insulin sensitizers addresses insulin resistance.

Related Experiment Videos

  • New short-acting insulinotropic agents offer improved convenience for glycemic control compared to sulfonylureas.

    • Conclusions:

    • Novel hypoglycemic agents provide new strategies for managing type 2 diabetes.
    • These agents aim to improve glycemic control and reduce long-term complications.